European Neuropsychopharmacology
Volume 20, Issue 6 , Pages 357-368 , June 2010

The involvement of GSK3β in bipolar disorder: Integrating evidence from multiple types of genetic studies

  • J.J. Luykx

      Affiliations

    • Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, B01.206, P.O. Box 85500, 3508 GA Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 88 7555555x3327; fax: +31 88 7555509.
    • ,
  • M.P.M. Boks

      Affiliations

    • Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, B01.206, P.O. Box 85500, 3508 GA Utrecht, The Netherlands
    • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    • ,
  • A.P.R. Terwindt

      Affiliations

    • Utrecht University/University Medical Center, Utrecht, The Netherlands
    • ,
  • S. Bakker

      Affiliations

    • Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, B01.206, P.O. Box 85500, 3508 GA Utrecht, The Netherlands
    • ,
  • R.S. Kahn

      Affiliations

    • Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, B01.206, P.O. Box 85500, 3508 GA Utrecht, The Netherlands
    • ,
  • R.A. Ophoff

      Affiliations

    • Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, B01.206, P.O. Box 85500, 3508 GA Utrecht, The Netherlands
    • Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
    • Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, California, United States

Received 4 October 2009 ,Revised 17 January 2010 ,Accepted 13 February 2010.

References 

  1. Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 2006;15:3132–3145
  2. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat. Rev. Genet. 2008;9:341–355
  3. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol. Psychiatry. 2002;7:405–411
  4. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry. 2008;13:197–207
  5. Baum AE, Hamshere M, Green E, Cichon S, Rietschel M, Noethen MM, et al. Meta-analysis of two genome-wide association studies of bipolar disorder reveals important points of agreement. Mol. Psychiatry. 2008;13:466–467
  6. Baysal BE, Potkin SG, Farr JE, Higgins MJ, Korcz J, Gollin SM, et al. Bipolar affective disorder partially cosegregates with a balanced t(9;11)(p24;q23.1) chromosomal translocation in a small pedigree. Am. J. Med. Genet. 1998;81:81–91
  7. Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C, et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci. Lett. 2005;376:51–55
  8. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology. 2007;32:1888–1902
  9. Bohm D, Hoffmann K, Laccone F, Wilken B, Dechent P, Frahm J, et al. Association of Jacobsen syndrome and bipolar affective disorder in a patient with a de novo 11q terminal deletion. Am. J. Med. Genet. 2006;140:378–382
  10. Bosetti F, Bell JM, Manickam P. Microarray analysis of rat brain gene expression after chronic administration of sodium valproate. Brain Res. Bull. 2005;65:331–338
  11. Bromberg A, Bersudsky Y, Levine J, Agam G. Global leukocyte DNA methylation is not altered in euthymic bipolar patients. J. Affect. Disord. 2009;118(1–3):234–239
  12. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386–389
  13. Cassidy F, Zhao C, Badger J, Claffey E, Dobrin S, Roche S, et al. Genome-wide scan of bipolar disorder and investigation of population stratification effects on linkage: support for susceptibility loci at 4q21, 7q36, 9p21, 12q24, 14q24, and 16p13. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007;144B:791–801
  14. Cavazzoni P, Alda M, Turecki G, Rouleau G, Grof E, Martin R, et al. Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatry Res. 1996;64:91–96
  15. De Luca V, Strauss J, Semeralul M, Huang S, Li PP, Warsh JJ, et al. Analysis of BDNF Val66Met allele-specific mRNA levels in bipolar disorder. Neurosci. Lett. 2008;441:229–232
  16. Dewachter I, Ris L, Jaworski T, Seymour CM, Kremer A, Borghgraef P, et al. GSK3ss, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at Serine-9. Neurobiol. Dis. 2009;35:193–200
  17. Ding L, Hegde AN. Expression of RGS4 splice variants in dorsolateral prefrontal cortex of schizophrenic and bipolar disorder patients. Biol. Psychiatry. 2009;65:541–545
  18. Duffy A, Turecki G, Grof P, Cavazzoni P, Grof E, Joober R, et al. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder. J. Psychiatry. Neurosci. 2000;25:353–358
  19. Eastwood SL, Harrison PJ. Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder. Neuropsychopharmacology. 2008;33:933–945
  20. Ekholm JM, Kieseppa T, Hiekkalinna T, Partonen T, Paunio T, Perola M, et al. Evidence of susceptibility loci on 4q32 and 16p12 for bipolar disorder. Hum. Mol. Genet. 2003;12:1907–1915
  21. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004;36:131–137
  22. Engstrom C, Astrom M, Nordqvist-Karlsson B, Adolfsson R, Nylander PO. Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Biol. Psychiatry. 1997;42:425–433
  23. Ertley RN, Bazinet RP, Lee HJ, Rapoport SI, Rao JS. Chronic treatment with mood stabilizers increases membrane GRK3 in rat frontal cortex. Biol. Psychiatry. 2007;61:246–249
  24. Etain B, Mathieu F, Rietschel M, Maier W, Albus M, McKeon P, et al. Genome-wide scan for genes involved in bipolar affective disorder in 70 European families ascertained through a bipolar type I early-onset proband: supportive evidence for linkage at 3p14. Mol. Psychiatry. 2006;11:685–694
  25. Fatemi SH, Reutiman TJ, Folsom TD. Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats. Schizophr. Res. 2009;111:138–152
  26. Ferreira MA, O'donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 2008;40(9):1056–1058
  27. Frey BN, Valvassori SS, Reus GZ, Martins MR, Petronilho FC, Bardini K, et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J. Psychiatry Neurosci. 2006;31:326–332
  28. Freyberg Z, Ferrando SJ, Javitch JA. Roles of the Akt/GSK-3 and Wnt Signaling Pathways in Schizophrenia and Antipsychotic Drug Action. Am. J. Psychiatry. 2009;(Electronic publication ahead of print)
  29. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. Is response to prophylactic lithium a familial trait?. J. Clin. Psychiatry. 2002;63:942–947
  30. Harwood AJ. Regulation of GSK-3: a cellular multiprocessor. Cell. 2001;105:821–824
  31. Herzberg I, Jasinska A, Garcia J, Jawaheer D, Service S, Kremeyer B, et al. Convergent linkage evidence from two Latin–American population isolates supports the presence of a susceptibility locus for bipolar disorder in 5q31–34. Hum. Mol. Genet. 2006;15:3146–3153
  32. Hirota T, Lewis WG, Liu AC, Lee JW, Schultz PG, Kay SA. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3beta. Proc. Natl. Acad. Sci. USA. 2008;105:20746–20751
  33. Iwamoto K, Bundo M, Washizuka S, Kakiuchi C, Kato T. Expression of HSPF1 and LIM in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. J. Hum. Genet. 2004;49:227–231
  34. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol. Psychiatry. 2004;9:406–416
  35. Kakiuchi C, Ishigaki S, Oslowski CM, Fonseca SG, Kato T, Urano F. Valproate, a mood stabilizer, induces WFS1 expression and modulates its interaction with ER stress protein GRP94. PLoS ONE. 2009;4:e4134
  36. Kang UG, Seo MS, Roh MS, Kim Y, Yoon SC, Kim YS. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. 2004;560:115–119
  37. Karege F, Schwald M, Papadimitriou P, Lachausse C, Cisse M. The camp-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder. J. Affect. Disord. 2004;79:187–192
  38. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA. 1996;93:8455–8459
  39. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch. Gen. Psychiatry. 2004;61:300–308
  40. Kuratomi G, Iwamoto K, Bundo M, Kusumi I, Kato N, Iwata N, et al. Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Mol. Psychiatry. 2008;13:429–441
  41. Lachman HM, Pedrosa E, Petruolo OA, Cockerham M, Papolos A, Novak T, et al. Increase in GSK3 beta gene copy number variation in bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007;144B:259–265
  42. Le-Niculescu H, Patel SD, Bhat M, Kuczenski R, Faraone SV, Tsuang MT, et al. Convergent functional genomics of genome-wide association data for bipolar disorder: comprehensive identification of candidate genes, pathways and mechanisms. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009;150B:155–181
  43. Levine J, Sela BA, Osher Y, Belmaker RH. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2005;29:1181–1191
  44. MacAyran JF, Brodie SG, Rao PN, O'connor MJ, Gray JA, Ciarimboli B, et al. Duplication 8q22.1-q24.1 associated with bipolar disorder and speech delay. Bipolar Disord. 2006;8:294–298
  45. MacDonald ML, Naydenov A, Chu M, Matzilevich D, Konradi C. Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disord. 2006;8:255–264
  46. Malatynska E, Knapp RJ. Dominant-submissive behavior as models of mania and depression. Neurosci. Biobehav. Rev. 2005;29:715–737
  47. Mamdani F, Groisman IJ, Alda M, Turecki G. Pharmacogenetics and bipolar disorder. Pharmacogenomics J. 2004;4:161–170
  48. Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G. Lithium response and genetic variation in the CREB family of genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008;147B:500–504
  49. Marcheco-Teruel B, Flint TJ, Wikman FP, Torralbas M, Gonzalez L, Blanco L, et al. A genome-wide linkage search for bipolar disorder susceptibility loci in a large and complex pedigree from the eastern part of Cuba. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006;141B:833–843
  50. Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S, et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr. Genet. 2006;16:49–50
  51. Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S, et al. A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32:204–208
  52. Matigian N, Windus L, Smith H, Filippich C, Pantelis C, McGrath J, et al. Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. Mol. Psychiatry. 2007;12:815–825
  53. McAuley EZ, Blair IP, Liu Z, Fullerton JM, Scimone A, Van Herten M, et al. A genome screen of 35 bipolar affective disorder pedigrees provides significant evidence for a susceptibility locus on chromosome 15q25-26. Mol. Psychiatry. 2008;14(5):492–500
  54. McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol. Ther. 2007;114:222–232
  55. McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res. 2007;1127:108–118
  56. McQueen MB, Devlin B, Faraone SV, Nimgaonkar VL, Sklar P, Smoller JW, et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am. J. Hum. Genet. 2005;77:582–595
  57. Middleton FA, Pato MT, Gentile KL, Morley CP, Zhao X, Eisener AF, et al. Genomewide linkage analysis of bipolar disorder by use of a high-density single-nucleotide-polymorphism (SNP) genotyping assay: a comparison with microsatellite marker assays and finding of significant linkage to chromosome 6q22. Am. J. Hum. Genet. 2004;74:886–897
  58. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 2008;82:696–711
  59. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 2000;9:1415–1423
  60. Morissette J, Villeneuve A, Bordeleau L, Rochette D, Laberge C, Gagne B, et al. Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in quebec points to a locus of major effect on chromosome 12q23-q24. Am. J. Med. Genet. 1999;88:567–587
  61. Mors O, Ewald H, Blackwood D, Muir W. Cytogenetic abnormalities on chromosome 18 associated with bipolar affective disorder or schizophrenia. Br. J. Psychiatry. 1997;170:278–280
  62. Naydenov AV, MacDonald ML, Ongur D, Konradi C. Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch. Gen. Psychiatry. 2007;64:555–564
  63. Niculescu AB, Kelsoe JR. Convergent functional genomics: application to bipolar disorder. Ann. Med. 2001;33:263–271
  64. Niculescu AB, Segal DS, Kuczenski R, Barrett T, Hauger RL, Kelsoe JR. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol. Genomics. 2000;4:83–91
  65. Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB, et al. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol. Psychiatry. 2004;9:1007–1029
  66. Olajossy M, Olajossy-Hilkesberger L, Tkaczuk-Wlach J. Bipolar affective disorder in a male with a deletion of Y chromosome — a case report. Bipolar Disord. 2005;7:298–301
  67. Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry. 2008;65:395–407
  68. Papolos DF, Faedda GL, Veit S, Goldberg R, Morrow B, Kucherlapati R, et al. Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder?. Am. J. Psychiatry. 1996;153:1541–1547
  69. Park N, Juo SH, Cheng R, Liu J, Loth JE, Lilliston B, et al. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol. Psychiatry. 2004;9:1091–1099
  70. Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, Lawrence J, et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am. J. Psychiatry. 2009;166:718–725
  71. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001;276:36734–36741
  72. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim. Biophys. Acta. 1992;1114:147–162
  73. Prickaerts J, Moechars D, Cryns K, Lenaerts I, Van Craenendonck H, Goris I, et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J. Neurosci. 2006;26:9022–9029
  74. Reardon W, Dunlop A, Holden ST, Blennerhassett R. Bipolar affective disorder associated with 11q24.2 disruption—a second report. Am. J. Med. Genet. 2007;143A:1263–1267
  75. Ross J, Berrettini W, Coryell W, Gershon ES, Badner JA, Kelsoe JR, et al. Genome-wide parametric linkage analyses of 644 bipolar pedigrees suggest susceptibility loci at chromosomes 16 and 20. Psychiatr. Genet. 2008;18:191–198
  76. Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszczynska-Rodziewicz A, Permoda A, et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry. 2005;38:166–170
  77. Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J. Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007;144B:820–823
  78. Saleem Q, Dash D, Gandhi C, Kishore A, Benegal V, Sherrin T, et al. Association of CAG repeat loci on chromosome 22 with schizophrenia and bipolar disorder. Mol. Psychiatry. 2001;6:694–700
  79. Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, Upmanyu R, et al. Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc. Natl. Acad. Sci. USA. 2009;106:7501–7506
  80. Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am. J. Hum. Genet. 2003;73:49–62
  81. Serretti A, Mandelli L. The genetics of bipolar disorder: genome ‘hot regions’, genes, new potential candidates and future directions. Mol. Psychiatry. 2008;13:742–771
  82. Serretti A, Lilli R, Lorenzi C, Franchini L, Smeraldi E. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int. J. Neuropsychopharmacol. 1998;1:125–129
  83. Serretti A, Lilli R, Lorenzi C, Franchini L, Di Bella D, Catalano M, et al. Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res. 1999;87:7–19
  84. Serretti A, Lorenzi C, Lilli R, Smeraldi E. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J. Psychiatr. Res. 2000;34:89–98
  85. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J. 2001;1:71–77
  86. Serretti A, Lorenzi C, Lilli R, Mandelli L, Pirovano A, Smeraldi E. Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants. Am. J. Med. Genet. 2002;114:370–379
  87. Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol. Psychiatry. 2008;64:89–97
  88. Shink E, Morissette J, Sherrington R, Barden N. A genome-wide scan points to a susceptibility locus for bipolar disorder on chromosome 12. Mol. Psychiatry. 2005;10:545–552
  89. Silberberg G, Levit A, Collier D, St Clair D, Munro J, Kerwin RW, et al. Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet. Genomics. 2008;18:403–412
  90. Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K, et al. Whole-genome association study of bipolar disorder. Mol. Psychiatry. 2008;13:558–569
  91. Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W, et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol. Psychiatry. 2009;14(8):755–763
  92. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 1996;6:1664–1668
  93. Steen VM, Gulbrandsen AK, Eiken HG, Berle JO. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. Pharmacogenetics. 1996;6:113–116
  94. Sutton LP, Honardoust D, Mouyal J, Rajakumar N, Rushlow WJ. Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J. Neurochem. 2007;102:153–169
  95. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362:798–805
  96. Turecki G, Alda M, Grof P, Martin R, Cavazzoni PA, Duffy A, et al. No association between chromosome-18 markers and lithium-responsive affective disorders. Psychiatry Res. 1996;63:17–23
  97. Venken T, Alaerts M, Souery D, Goossens D, Sluijs S, Navon R, et al. Chromosome 10q harbors a susceptibility locus for bipolar disorder in Ashkenazi Jewish families. Mol. Psychiatry. 2008;13:442–450
  98. Washizuka S, Iwamoto K, Kakiuchi C, Bundo M, Kato T. Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. Neurosci. Res. 2009;63:199–204
  99. Wilson GM, Flibotte S, Chopra V, Melnyk BL, Honer WG, Holt RA. DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling. Hum. Mol. Genet. 2006;15:743–749
  100. WTCCC . Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature. 2007;447:661–678
  101. Yanagita T, Maruta T, Nemoto T, Uezono Y, Matsuo K, Satoh S, et al. Chronic lithium treatment up-regulates cell surface Na(V)1.7 sodium channels via inhibition of glycogen synthase kinase-3 in adrenal chromaffin cells: enhancement of Na(+) influx, Ca(2+) influx and catecholamine secretion after lithium withdrawal. Neuropharmacology. 2009;57(3):311–321
  102. Yingwei Mao XG, Frank CL, Madison JM, Koehler AN, Doud MK, Tassa C, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3β/β-catenin signaling. Cell. 2009;136:1017–1031
  103. Yoon IS, Li PP, Siu KP, Kennedy JL, MacCiardi F, Cooke RG, et al. Altered TRPC7 gene expression in bipolar-I disorder. Biol. Psychiatry. 2001;50:620–626
  104. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell. 2005;120:137–149
  105. Zandi PP, Badner JA, Steele J, Willour VL, Miao K, MacKinnon DF, et al. Genome-wide linkage scan of 98 bipolar pedigrees and analysis of clinical covariates. Mol. Psychiatry. 2007;12:630–639
  106. Zandi PP, Belmonte PL, Willour VL, Goes FS, Badner JA, Simpson SG, et al. Association study of Wnt signaling pathway genes in bipolar disorder. Arch. Gen. Psychiatry. 2008;65:785–793
  107. Zhang D, Cheng L, Qian Y, Alliey-Rodriguez N, Kelsoe JR, Greenwood T, et al. Singleton deletions throughout the genome increase risk of bipolar disorder. Mol. Psychiatry. 2009;14:376–380
  108. Zhou X, Barrett TB, Kelsoe JR. Promoter variant in the GRK3 gene associated with bipolar disorder alters gene expression. Biol. Psychiatry. 2008;64:104–110
  109. Zhou X, Tang W, Greenwood TA, Guo S, He L, Geyer MA, et al. Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS ONE. 2009;4:e5196

PII: S0924-977X(10)00041-6

doi: 10.1016/j.euroneuro.2010.02.008

European Neuropsychopharmacology
Volume 20, Issue 6 , Pages 357-368 , June 2010

Article Tools